Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CD19 t-haNK cells |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
CD19 t-haNK cells are activated natural killer (NK) cells engineered to express a high affinity Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which potentially induce tumor cell killing (PMID: 35400595). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CD19 t-haNK cells | CD19 t-haNK cells | 0 | 0 |
| CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | CD19 t-haNK cells Nogapendekin alfa inbakicept Rituximab | 0 | 1 |
| CD19 t-haNK cells + Rituximab | CD19 t-haNK cells Rituximab | 0 | 1 |